• SENSEX
    NIFTY 50
Market

Tuesday's top brokerage calls: IT sector, hospitals and more

Updated : 2020-12-22 08:57:51

Among brokerages, Goldman Sachs resumed coverage on the Indian IT sector with a strong positive outlook while Jefferies initiated coverage with a 'buy' call on Max Health and 'hold' calls on Apollo Hospitals and Fortis. Here are the top brokerage calls for today:

 Goldman Sachs on IT:  The brokerage resumed coverage on the Indian IT sector with a strong positive outlook. It says that the third wave of the IT outsourcing cycle is ahead. It has a 'buy' call on Infosys, MindTree, TCS, Tech Mahindra and Mphasis; and a 'sell' call on Wipro.
Goldman Sachs on IT: The brokerage resumed coverage on the Indian IT sector with a strong positive outlook. It says that the third wave of the IT outsourcing cycle is ahead. It has a 'buy' call on Infosys, MindTree, TCS, Tech Mahindra and Mphasis; and a 'sell' call on Wipro.
 Jefferies on Hospitals : The brokerage initiated coverage with a 'buy' call on Max Health and 'hold' calls on Apollo Hospitals and Fortis. It expects FY22 to be a recovery year for Indian healthcare.
Jefferies on Hospitals: The brokerage initiated coverage with a 'buy' call on Max Health and 'hold' calls on Apollo Hospitals and Fortis. It expects FY22 to be a recovery year for Indian healthcare.
 Nomura on Indian Economy:  The brokerage retains optimism of an economic upcycles into 2021. It added that fiscal expenditure compression and a weak global outlook are some short-term headwinds.
Nomura on Indian Economy: The brokerage retains optimism of an economic upcycles into 2021. It added that fiscal expenditure compression and a weak global outlook are some short-term headwinds.
 Nomura on Pharma : As per the brokerage, prescriptions have increased QoQ for key products in the US across all companies. It expects a rise in market share of Dr Reddy's as pharma firm Indivior loses preferential status.
Nomura on Pharma: As per the brokerage, prescriptions have increased QoQ for key products in the US across all companies. It expects a rise in market share of Dr Reddy's as pharma firm Indivior loses preferential status.
Live TV

recommended for you

Ask Our Experts CNBC TV18

Advertisement